CARTAS
CIENTÍFICAS
503
Table
1
Baseline
and
clinical
data
of
the
eight
patients
studied.
Patient
number
Diagnosis
Gender
Age
(years)
Day
Natremia
before
tolvaptan
Natremia
24
h
after
tolvaptan
Natremia
24
h
Natremia
48
h
after
tolvaptan
24
h
fluid
balance
(ml)
Follow
up
doses
1
ICH
Male
45
15
132
135
3
135
−
1440
Yes
2
*
ICH
Female
55
11
127
142
15
139
−
3425
No
3
TBI
Female
45
12
131
138
7
137
−
1850
Yes
4
SAH
Male
48
21
132
137
5
136
−
122
Yes
5
SAH
Female
57
8
133
138
5
136
−
744
Yes
6
Cerebral
abcess
Male
28
30
132
140
8
140
−
4372
No
7
SAH
Male
50
19
131
136
5
137
−
1726
No
8
TBI
Male
29
25
134
136
2
136
−
456
Yes
Median
(IQR)
46
(33---54)
17
(11---24)
132
(131---133)
138
(136---140)
5
(4---8)
136
(136---138)
−
1600
(
−
3000
to
−
500)
ICH:
intracerebral
hemorrhage;
TBI
:
traumatic
brain
injury;
SAH:
subarachnoid
hemorrhage.
*
Means
that
this
patient
received
a
single
15
mg-dose.
Conflict
of
interest
Dr.
Llompart-Pou
declares
having
received
honoraria
from
Otsuka
for
participating
in
a
consensus
document
in
the
management
of
hyponatremia
in
critically
ill
patients.
Dr.
Pérez-Bárcena,
Novo
and
Raurich
declare
no
financial
disclosure.
Bibliografía
1.
Kleindienst
A,
Hannon
MJ,
Buchfelder
M,
Verbalis
JG.
Hypona-
tremia
in
neurotrauma:
the
role
of
vasopressin.
J
Neurotrauma.
2016;33:615---24.
2.
Jeon
SB,
Choi
HA,
Lesch
C,
Kim
MC,
Badjatia
N,
Claassen
J,
et
al.
Use
of
oral
vasopressin
V2
receptor
antagonist
for
hyponatremia
in
acute
brain
injury.
Eur
Neurol.
2013;70:142---8.
3.
Hannon
MJ,
Finucane
FM,
Sherlock
M,
Agha
A,
Thompson
CJ.
Clinical
review:
disorders
of
water
homeostasis
in
neurosurgical
patients.
J
Clin
Endocrinol
Metab.
2012;97:1423---33.
4.
Giuliani
C,
Peri
A.
Effects
of
hyponatremia
on
the
brain.
J
Clin
Med.
2014;3:1163---77.
5.
Corona
G,
Giuliani
C,
Verbalis
JG,
Forti
G,
Maggi
M,
Peri
A.
Hyponatremia
improvement
is
associated
with
a
reduced
risk
of
mortality:
evidence
from
a
meta-analysis.
PLOS
ONE.
2015;10:e0124105.
6.
Schrier
RW,
Gross
P,
Gheorghiade
M,
Berl
T,
Verbalis
JG,
Czer-
wiec
FS,
et
al.,
SALT
Investigators.
Tolvaptan,
a
selective
oral
vasopressin
V2-receptor
antagonist,
for
hyponatremia.
N
Engl
J
Med.
2006;355:2099---112.
7.
Verbalis
JG,
Greenberg
A,
Burst
V,
Haymann
JP,
Johanns-
son
G,
Peri
A,
et
al.
Diagnosing
and
treating
the
syndrome
of
inappropriate
antidiuretic
hormone
secretion.
Am
J
Med.
2016;129:537.e9---23.
8.
Verbalis
JG,
Goldsmith
SR,
Greenberg
A,
Korzelius
C,
Schrier
RW,
Sterns
RH,
et
al.
Diagnosis,
evaluation,
and
treatment
of
hypo-
natremia:
expert
panel
recommendations.
Am
J
Med.
2013;126
10
Suppl.
1:S1---42.
9.
Runkle
I,
Villabona
C,
Navarro
A,
Pose
A,
Formiga
F,
Tejedor
A,
et
al.,
European
Hyponatremia
Network.
The
treatment
of
hyponatremia
secondary
to
the
syndrome
of
inap-
propriate
antidiuretic
hormone
secretion.
Med
Clin
(Barc).
2013;141:507.e1---10.
10.
http://www.ema.europa.eu/docs/es
ES/document
library/
EPAR
-
Product
Information/human/000980/WC500048716.pdf
[accessed
14.10.16].
11.
Kleinschmidt-Demasters
BK,
Rojiani
AM,
Filley
CM.
Central
and
extrapontine
myelinolysis:
then
.
.
.
and
now.
J
Neuropathol
Exp
Neurol.
2006;65:1---11.
J.A.
Llompart-Pou
a
,
b
,
∗
,
J.
Pérez-Bárcena
a
,
b
,
M.
Novo
a
,
J.M.
Raurich
a
a
Servei
de
Medicina
Intensiva,
Hospital
Universitari
Son
Espases,
Palma
de
Mallorca,
Spain
b
Instituto
de
Investigación
Sanitaria
de
Palma
(IdISPa),
Palma
de
Mallorca,
Spain
∗
Corresponding
author.
E-mail
address:
juanantonio.llompart@ssib.es
(J.A.
Llompart-Pou).
http://dx.doi.org/10.1016/j.medin.2016.11.007
0210-5691/
©
2016
Elsevier
Espa
̃
na,
S.L.U.
y
SEMICYUC.
All
rights
reserved.